FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304014009> ?p ?o ?g. }

• W4304014009 endingPage "1287" @default.
• W4304014009 startingPage "1275" @default.
• W4304014009 abstract "Immune checkpoint inhibitors (ICIs) are effective for the treatment of various cancers, but can lead to immune-mediated hepatotoxicity (IMH). The aim of this study was to analyze the risk factors for IMH in cancer patients treated with ICIs.The PubMed, EMBASE, and Cochrane Library databases were searched. Eligible studies should compare the difference between patients who developed and did not develop IMH. Odds ratio (OR) and weighted mean difference (WMD) with 95% confidence interval (CI) were calculated.Among the 5030 papers initially identified, 13 studies were included. Meta-analyses indicated that age (WMD: -5.200, 95%CI: -7.481 to -2.919), history of ICIs treatment (OR: 4.491, 95%CI: 2.205 to 9.145), ICIs combination therapy (OR: 5.353, 95%CI: 1.663 to 17.232), and aspartate aminotransferase (AST) level (WMD: 5.039, 95%CI: 1.220 to 8.857) were significantly associated with the risk of any grade IMH; and age (WMD: -5.193; 95%CI: -9.669 to -0.718) was significantly associated with the risk of grade ≥3 IMH. These findings provide the evidence for identifying patients at a high risk of IMH. Appropriate intervention may be given to prevent from IMH in high-risk patients, thereby enabling ICIs to achieve an expected tumor response.PLAIN LANGUAGE SUMMARYAt present, immune checkpoint inhibitors (ICIs) are one of the most important treatment choices for cancer. ICIs can enhance the antitumor response by inhibiting the immune checkpoint pathway. The immune checkpoint pathways include CTLA-4 pathway and PD-1 pathway, which inhibit the activation of the immune system. Among them, CTLA-4 pathway stops potentially autoreactive T-cell at the initial stage of T-cell activation, and the PD-1 pathway regulates activated T-cell at the later stage of an immune response. However, excessively enhanced immune activity may cause immune cells to attack health organs like the liver, developing immune-mediated hepatotoxicity (IMH), which may affect the tumor response of ICIs. Therefore, it is crucial to explore the risk factors for IMH in cancer patients treated with ICIs. We searched 3 medical databases: PubMed, EMBASE, and Cochrane Library, and then the studies that evaluated the difference between patients who developed and did not develop IMH were included in our systematic review and meta-analysis. The meta-analyses showed younger patients, patients with history of ICIs treatment, patients who had ICIs combination therapy, and patients with higher liver enzyme AST levels were more likely to develop IMH. Therefore, doctors should pay more attention to the patients at high-risk for IMH with the goal of improving the chances that they achieve a good response from their ICIs therapy." @default.
• W4304014009 created "2022-10-10" @default.
• W4304014009 creator A5004503278 @default.
• W4304014009 creator A5008457497 @default.
• W4304014009 creator A5037581187 @default.
• W4304014009 creator A5061180661 @default.
• W4304014009 creator A5075449781 @default.
• W4304014009 creator A5090517331 @default.
• W4304014009 creator A5090644360 @default.
• W4304014009 date "2022-10-03" @default.
• W4304014009 modified "2023-10-18" @default.
• W4304014009 title "Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis" @default.
• W4304014009 cites W1809627231 @default.
• W4304014009 cites W2015085911 @default.
• W4304014009 cites W2020684181 @default.
• W4304014009 cites W2044200527 @default.
• W4304014009 cites W2076067786 @default.
• W4304014009 cites W2099560139 @default.
• W4304014009 cites W2112121482 @default.
• W4304014009 cites W2263759961 @default.
• W4304014009 cites W2466711473 @default.
• W4304014009 cites W2527905628 @default.
• W4304014009 cites W2592692971 @default.
• W4304014009 cites W2608694312 @default.
• W4304014009 cites W2672184770 @default.
• W4304014009 cites W2741316449 @default.
• W4304014009 cites W2775503072 @default.
• W4304014009 cites W2783137027 @default.
• W4304014009 cites W2891486030 @default.
• W4304014009 cites W2897963483 @default.
• W4304014009 cites W2900752818 @default.
• W4304014009 cites W2912495668 @default.
• W4304014009 cites W2925446385 @default.
• W4304014009 cites W2945341460 @default.
• W4304014009 cites W2948362628 @default.
• W4304014009 cites W2990914982 @default.
• W4304014009 cites W3003238214 @default.
• W4304014009 cites W3011161235 @default.
• W4304014009 cites W3012305117 @default.
• W4304014009 cites W3013916210 @default.
• W4304014009 cites W3023745224 @default.
• W4304014009 cites W3044563839 @default.
• W4304014009 cites W3092802874 @default.
• W4304014009 cites W3104085480 @default.
• W4304014009 cites W3107630928 @default.
• W4304014009 cites W3108004653 @default.
• W4304014009 cites W3113354312 @default.
• W4304014009 cites W3131365592 @default.
• W4304014009 cites W3159932777 @default.
• W4304014009 cites W3186399754 @default.
• W4304014009 cites W3205376127 @default.
• W4304014009 cites W3205615497 @default.
• W4304014009 cites W3207128841 @default.
• W4304014009 cites W4200561263 @default.
• W4304014009 cites W3170799867 @default.
• W4304014009 doi "https://doi.org/10.1080/14740338.2022.2134854" @default.
• W4304014009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36214583" @default.
• W4304014009 hasPublicationYear "2022" @default.
• W4304014009 type Work @default.
• W4304014009 citedByCount "2" @default.
• W4304014009 countsByYear W43040140092023 @default.
• W4304014009 crossrefType "journal-article" @default.
• W4304014009 hasAuthorship W4304014009A5004503278 @default.
• W4304014009 hasAuthorship W4304014009A5008457497 @default.
• W4304014009 hasAuthorship W4304014009A5037581187 @default.
• W4304014009 hasAuthorship W4304014009A5061180661 @default.
• W4304014009 hasAuthorship W4304014009A5075449781 @default.
• W4304014009 hasAuthorship W4304014009A5090517331 @default.
• W4304014009 hasAuthorship W4304014009A5090644360 @default.
• W4304014009 hasConcept C121608353 @default.
• W4304014009 hasConcept C126322002 @default.
• W4304014009 hasConcept C143998085 @default.
• W4304014009 hasConcept C156957248 @default.
• W4304014009 hasConcept C197934379 @default.
• W4304014009 hasConcept C2776478404 @default.
• W4304014009 hasConcept C44249647 @default.
• W4304014009 hasConcept C71924100 @default.
• W4304014009 hasConcept C95190672 @default.
• W4304014009 hasConceptScore W4304014009C121608353 @default.
• W4304014009 hasConceptScore W4304014009C126322002 @default.
• W4304014009 hasConceptScore W4304014009C143998085 @default.
• W4304014009 hasConceptScore W4304014009C156957248 @default.
• W4304014009 hasConceptScore W4304014009C197934379 @default.
• W4304014009 hasConceptScore W4304014009C2776478404 @default.
• W4304014009 hasConceptScore W4304014009C44249647 @default.
• W4304014009 hasConceptScore W4304014009C71924100 @default.
• W4304014009 hasConceptScore W4304014009C95190672 @default.
• W4304014009 hasIssue "10" @default.
• W4304014009 hasLocation W43040140091 @default.
• W4304014009 hasLocation W43040140092 @default.
• W4304014009 hasOpenAccess W4304014009 @default.
• W4304014009 hasPrimaryLocation W43040140091 @default.
• W4304014009 hasRelatedWork W1983574452 @default.
• W4304014009 hasRelatedWork W2082392604 @default.
• W4304014009 hasRelatedWork W2127879534 @default.
• W4304014009 hasRelatedWork W2569856009 @default.
• W4304014009 hasRelatedWork W3116417372 @default.
• W4304014009 hasRelatedWork W3124218749 @default.

• next